Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...
Immunomic Therapeutics begins patient dosing in phase 1 trial of ITI-9001 to treat Japanese cedar pollen allergy: Rockville, Maryland Monday, July 6, 2026, 11:00 Hrs [IST] Immunom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results